Filing Flows › Spero Therapeutics (SPRO) › Stock forecast & fair value
Spero Therapeutics (SPRO) stock forecast and price target
Spero Therapeutics (SPRO) trades at $1.03. 3 analysts' median price target is $6.00 (+483%), from $4.00 to $6.00.
Spero Therapeutics' latest quarter
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for SPRO stock?
The median of 3 analysts' 12-month targets is $6.00, +483% from $1.03; the range is $4.00 to $6.00. The average rating is buy.
Does Spero Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is SPRO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.